Target intelligence / Profile preview

Glial scar components (GSC)

Target
GSC
Molecular classification
Extracellular matrix protein, Proteoglycan, Cell adhesion molecule, Cytokine, Other
01

Overview

Glial scar components refer to the complex assembly of cells and extracellular matrix (ECM) molecules that form a physical and chemical barrier following central nervous system (CNS) injury. The primary constituents include reactive astrocytes, microglia, and a dense matrix of chondroitin sulfate proteoglycans (CSPGs) such as neurocan and brevican, which are potent inhibitors of axonal regeneration. While the scar initially serves a protective role by sealing the injury site and re-establishing the blood-brain barrier, its persistence prevents functional recovery by blocking neurite outgrowth and synapse formation. Therapeutic strategies targeting these components aim to enzymatically degrade inhibitory sugars, modulate astrocyte reactivity, or block the signaling receptors (like PTPσ) that mediate growth cone collapse. Successfully modifying the glial scar environment is a major focus in developing treatments for spinal cord injury and stroke to facilitate neural plasticity and repair.

Other names
Astrogliotic scar componentsPerilesional scarReactive gliosis componentsInhibitory extracellular matrix of the CNS
02

Mechanism of action

Degradation of inhibitory chondroitin sulfate proteoglycans (CSPGs), inhibition of RhoA/ROCK signaling pathways to overcome neurite outgrowth inhibition, and modulation of reactive astrocyte phenotypes to promote a permissive environment for regeneration.

03

Biological functions

Wound healingAxon guidance inhibitionInflammatory responseStructural supportBlood-brain barrier repair
04

Disease associations

Spinal cord injuryTraumatic brain injuryStrokeMultiple sclerosisNeurodegenerative disease
05

Safety considerations

Disruption of the blood-brain barrier (BBB) integrityUncontrolled axonal sprouting leading to neuropathic painExacerbation of neuroinflammationPotential for increased lesion spread if the protective barrier is removed too early
06

Interacting drugs

Chondroitinase ABC

4 more in the full profile.

07

Biomarkers

Glial fibrillary acidic protein (GFAP)Chondroitin sulfate proteoglycans (CSPGs)VimentinNeurofilament light chain (NfL)S100B

Beyond the preview

Go deeper on Glial scar components (GSC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glial scar components (GSC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call